Helene Hartman is the co-founder of Transient Pharma AB, with extensive experience in technology, product, and business development in multinational settings. She is also the founder and CEO of Xinnate AB, a biotech company advancing its primary drug candidate through clinical development. Helene has served on Boards of Directors in the financial and life science sectors.

Artur Schmidtchen is the co-founder of Transient Pharma AB. He is a professor and Head of Dermatology at Lund University, and a senior consultant at Skåne University Hospital. With a profound understanding of science and clinical needs, he brings extensive experience and a broad network in the scientific and clinical communities.

Christian Kjellman has >20 years of experience in drug development from discovery, through early- and late-stage clinical development, registration, and commercialization. He has been leading R&D, Medical and Commercial teams in his role as Chief Scientific Officer and Chief Operating Officer at Hansa Biopharma (STO: HNSA) and holds a PhD in Tumor Immunology from Lund University.

Anna-Karin has >20 years of experience in drug development from discovery, through early- and late-stage clinical development, to registration, and commercialization. She has been holding the positions of Manager Preclinical R&D and Project Director at Cartela AB, and Director Preclinical R&D and Director Project Management at Camurus AB. Anna-Karin has a PhD in Medical Genetics from Uppsala University.

Ganna Petruk is a Senior Research Scientist at the Division of Dermatology at Lund University, with a PhD in Biotechnology and a Docentship in Experimental Dermatology. She brings extensive experience in experimental and translational research, specializing in the development of drugs based on antimicrobial peptides designed for systemic use. Her research background spans biophysics, biochemistry, cell biology, and in vivo work, with expertise in developing in vitro and in vivo models for the screening of antimicrobial agents.

Bo Benell is active in international commercial law servicing clients in Sweden and abroad through his law firm Advokatbyrån Bo Benell. Bo has long experience from work in Boards of directors in various businesses.

Artur Schmidtchen is the co-founder of Transient Pharma and Xinnate AB. He is a professor and Head of Dermatology at Lund University, and a senior consultant at Skåne University Hospital. With a profound understanding of science and clinical needs, he brings extensive experience and a broad network in the scientific and clinical communities.